Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, MA 02115, USA.
Expert Rev Proteomics. 2011 Oct;8(5):577-89. doi: 10.1586/epr.11.48.
The development of proteomic technologies that display a wide variety of antigenic structures has led to the identification of autoantibodies to cancer-derived tumor antigens. These autoantibodies have been detected in sera from patients with multiple cancer types, and are being evaluated as biomarkers for early cancer detection. It is not known whether these antibodies also contribute to active immune surveillance or even tumorigenicity of developing tumors. Here, we review which tumor antigen-specific antibodies are prognostic biomarkers of cancer outcome, and emerging proteomic methods for the isolation and cloning of these antibodies for potential molecular diagnostics and therapeutics.
蛋白质组学技术的发展展示了多种多样的抗原结构，从而鉴定了针对癌症来源的肿瘤抗原的自身抗体。这些自身抗体已在多种癌症类型患者的血清中被检测到，并被评估为早期癌症检测的生物标志物。目前尚不清楚这些抗体是否也有助于正在发展的肿瘤的主动免疫监视甚至肿瘤发生。在这里，我们回顾了哪些肿瘤抗原特异性抗体是癌症预后的生物标志物，并介绍了新兴的蛋白质组学方法，用于分离和克隆这些抗体，以用于潜在的分子诊断和治疗。
